We demonstrated that albumin-hitchhiking nanobodies enhanced the potency and efficacy of a diABZI STING agonist and we showcased the versatility of the system by introducing an PD-L1 binding nanobody that affords increased tumor targeting and immune checkpoint inhibition to further potentiate antitumor immunity and efficacy. This evidence concerns the gene CD274 and neoplasm.